NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Assembly Biosciences, Inc. (ASMB) Stock Analysis

Assembly Biosciences, Inc. (ASMB) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ASMB

$20.46

−$0.73 (−3.45%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ASMB with… →

ASMB Key Statistics

As of Oct 21, 2026
Trading
Open
$21.42
Previous Close
$21.19
Day's Range
20.38–21.92
52-Week Range
19.94–39.71
Volume
234.77K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.16
Valuation
Market Cap
$416.58M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
5.57
Financials (FY)
Revenue (FY)
$72.30M+153.52%
Net Income (FY)
−$6.12M
Profit marginThe share of revenue left as profit after all costs and taxes.
−0.06%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
20.36M
1-Year Return
−27.98%
Dividend and dates
Avg Volume
285.40K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ASMB closed at $20.46, −27.98% over 1 year.

Assembly Biosciences, Inc. (ASMB) has a market capitalization of $416.58M.

In fiscal 2025, ASMB reported revenue of $72.30M.

ASMB Stock Return by Calendar Year

Assembly Biosciences, Inc. (ASMB) 10-year return: what $10,000 became

1 year
$10,000 $7,202
−27.98%
5 years
$10,000 $5,279
−47.21%
10 years
$10,000 $1,291
−87.09%

If you had invested $10,000 in Assembly Biosciences, Inc. (ASMB) 10 years ago, at the close on October 21, 2016, it would have been worth $1,291 at the close on October 21, 2026: −87.09% in total, −18.51% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−39.84%
2025+115.53%
2024+60.37%
2023−36.92%
2022−44.21%
2021−61.49%
2020−70.43%
2019−9.55%
2018−50.01%
2017+272.43%
2016 (partial year)+107.34%

As of October 21, 2026.

ASMB Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$72.30M−$6.12M−8.5%
2024$28.52M−$40.18M−140.9%
2023$7.16M−$61.23M−854.8%
2022$0.00−$93.09M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$72.30M—−$12.12M−$6.12M−8.5%
2024$28.52M—−$45.42M−$40.18M−140.9%
2023$7.16M—−$64.65M−$61.23M−854.8%
2022$0.00—−$94.11M−$93.09M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ASMB Valuation vs Biotechnology Median

Median of 608 stocks
MetricASMBBiotechnology medianvs median
P/S ratio5.5713.3058% below
Profit margin−0.06%−38.31%38.3 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Assembly Biosciences, Inc. (ASMB) is capitalised at $416.58M on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 73.

Over the past 52 weeks the price has ranged from $19.94 to $39.71. The most recent close on file for ASMB is $20.46, dated October 21, 2026. That is −$0.73 (−3.45%) against the previous close. The latest close sits 2.61% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $72.30M. Against the prior fiscal year total of $28.52M, that is a change of +153.52%. The same year closed with a net loss of $6.12M. The reported profit margin is −0.06%. That is 38.3 percentage points above the Biotechnology median of −38.31%.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $72.30M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 5.57. On price-to-sales that is 58.15% below the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

Over the trailing twelve months the total return is −27.98%. Measured over 10 years, that is −18.51% a year compounded. Beta against the wider market is reported at 1.16. Daily returns over the trailing 10 years annualize to a volatility of 70.7%.

Growth & Income

No dividend is on file for ASMB.

So far in 2026 the total return is −39.84%. Across the complete calendar years on file, 2017 returned +272.43% and 2020 returned −70.43%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Assembly Biosciences, Inc. (ASMB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Assembly Biosciences, Inc. ASMB $416.58M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Assembly Biosciences, Inc.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Visit website →